Article
Medicine, Research & Experimental
Deeba Naz, Sajjad Ur Rahman, Muhammad Aamir Aslam, Faqir Muhammad
Summary: The immune system fights against deadly pathogens that can cause severe health issues and even death. Antibodies play a crucial role in eliminating pathogens and protecting against future diseases. Understanding the interaction between Fc receptors and antibodies has led to the development of immune complex vaccines, which have been successful in preventing and treating viral and bacterial diseases. However, more research is needed to establish a connection between laboratory findings and clinical applications to ensure its effectiveness and safety in vivo.
MEDICAL HYPOTHESES
(2023)
Article
Medicine, Research & Experimental
Amir Abbas Momtazi-Borojeni, Maciej Banach, Sayed Abbas Tabatabaei, Amirhossein Sahebkar
Summary: The antiPCSK9 vaccine is safe and does not have adverse effects on the function of different organs and blood levels of cellular and biochemical biomarkers in healthy mice.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Oncology
Ke-Tao Jin, Bo Chen, Yu-Yao Liu, H. uan-Rong Lan, Jie-Ping Yan
Summary: Colorectal cancer is the third most common cancer globally with immunotherapy, including monoclonal antibodies and CAR-T cells, emerging as novel therapeutic approaches. Both monoclonal antibodies and CAR-T cells have beneficial anti-tumor effects on CRC by eliciting immune responses against tumor cells.
CANCER CELL INTERNATIONAL
(2021)
Review
Immunology
Wenqing Jia, Tao Zhang, Haiyan Huang, Haoran Feng, Shaodong Wang, Zichao Guo, Zhiping Luo, Xiaopin Ji, Xi Cheng, Ren Zhao
Summary: This review provides a brief summary of different categories of colorectal cancer (CRC) vaccines and presents current outcomes of relevant clinical trials. It particularly focuses on recent advances in nanovaccines and neoantigen vaccines, which represent the trend and emphasis in CRC vaccine development.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Engineering, Biomedical
Qiu-Ling Zhang, Sheng Hong, Xue Dong, Di-Wei Zheng, Jun-Long Liang, Xue-Feng Bai, Xia-Nan Wang, Zi-Yi Han, Xian-Zheng Zhang
Summary: This study presents a strategy for simplifying antigen presentation by extracellular degradation of antigen proteins into peptides, leading to improved utilization of cancer antigens and enhanced cancer immunity. The approach demonstrates potential for personalized anti-cancer therapy and has implications for expanding immunology fields and translational medicine.
Article
Oncology
Carmen Aguilar-Gurrieri, Ana Barajas, Carla Rovirosa, Raquel Ortiz, Victor Urrea, Nuria de la Iglesia, Bonaventura Clotet, Julia Blanco, Jorge Carrillo
Summary: Neoantigens are tumor-specific antigens that can elicit a specific immune response. They have potential for the development of personalized cancer vaccines. The presentation of neoantigens to T cells is influenced by vaccine delivery strategies, including the use of specific linkers. The efficiency of neoantigen processing and presentation by MHC-I molecules can be improved with alanine-based linkers.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Chemistry, Multidisciplinary
Yunfei Yi, Mian Yu, Wen Li, Dunwan Zhu, Lin Mei, Meitong Ou
Summary: The development of therapeutic cancer vaccines using nanotechnology has great potential in improving the limitations of current immunotherapies. Nanoparticles enhance vaccine stability and antigen recognition through their small size, while surface modifications allow targeted delivery. Nanocarriers with adjuvant effect also improve vaccine efficacy. Additionally, nanoparticle-mediated chemotherapy and radiotherapy induce the release of tumor antigens, simulating anti-tumor immune responses. These vaccine-like nanomedicines can effectively eliminate tumors and prevent recurrence and metastasis. This article presents recent advancements in nanoparticle-based antigen delivery for in situ anti-tumor vaccination and discusses the remaining opportunities and challenges for clinical translation.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Pharmacology & Pharmacy
Deying Yang, Xiang Luo, Qinghai Lian, Lingqiang Gao, Chengxin Wang, Xiaoxiao Qi, Rong Zhang, Zhongqiu Liu, Guochao Liao
Summary: This study presents a new strategy for self-adjuvanting vaccine development using different types of covalently-linked immunostimulants as the carrier molecule. A three-component vaccine (MPLA-Tn-KRN7000) containing the TLR4 ligand MPLA and the iNKT cell agonist KRN7000 was designed and synthesized, expanding the field of fully synthetic self-adjuvanting vaccines. The immunological evaluation showed that MPLA-Tn-KRN7000 induced robust Tn-specific and T cell-dependent immunity.
ACTA PHARMACEUTICA SINICA B
(2022)
Review
Oncology
Ya-Juan Zhu, Xiong Li, Ting-Ting Chen, Jia-Xiang Wang, Yi-Xin Zhou, Xiao-Li Mu, Yang Du, Jia-Ling Wang, Jie Tang, Ji-Yan Liu
Summary: Neoantigens, as cancer-specific aberrant peptides, can trigger robust immune response and hold great promise as an effective treatment approach for patients with CRC.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Kevin T. Lynch, Gabriella C. Squeo, William J. Kane, Max O. Meneveau, Gina Petroni, Walter C. Olson, Kimberly A. Chianese-Bullock, Craig L. Slingluff, Eugene F. Foley, Charles M. Friel
Summary: Checkpoint-blockade therapy (CBT) is approved for select colorectal cancer (CRC) patients, but additional immunotherapeutic options are needed. Vaccination with carcinoembryonic antigen (CEA) and Her2/neu (Her2) peptides was found to be well tolerated and immunogenic in participants with advanced CRC. Adverse events were mainly mild, with 70% of participants showing immune response to the peptides and a median overall survival of 16 months. Further study is warranted to assess the clinical benefits of vaccination in advanced CRC.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Pharmacology & Pharmacy
Pierre Machy, Erwan Mortier, Stephane Birkle
Summary: Ganglioside GD2, a complex glycolipid located on the cell membrane, exhibits diverse expression patterns and functions. Its overexpression in cancer enhances cell survival and invasion, while also contributing to T-cell dysfunction and functioning as an immune checkpoint. These cancer-associated functions make GD2 a potential target for immunotherapy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Jie Zhang, Biao Fan, Guoliang Cao, Wenping Huang, Fuhao Jia, Guangjun Nie, Hai Wang
Summary: This study developed a personalized DC-mimicking nanovaccine for stimulating TAAs-specific T cell populations. By inducing BMDCs maturation and delivering TAAs through nanostructures, the nanoDCs efficiently generated potent antigen-specific T cell responses, leading to inhibition of tumor growth and metastases formation.
ADVANCED MATERIALS
(2022)
Article
Oncology
Tom J. Harryvan, Marten Visser, Linda de Bruin, Leonie Plug, Lisa Griffioen, Arend Mulder, Peter A. van Veelen, Gerbrand J. van Der Heden van Noort, Marlieke Lm Jongsma, Miranda H. Meeuwsen, Emmanuel Jhj Wiertz, Saskia J. Santegoets, James Ch Hardwick, Thorbald Van Hall, Jacques Neefjes, Sjoerd H. Van der Burg, Lukas J. A. C. Hawinkels, Els M. E. Verdegaal
Summary: This study found that human CRC-derived CAFs have an enhanced ability to cross-present antigens, which involves the participation of lysosomal protease cathepsin S. The interaction between cross-presenting CAFs and CD8+ T cells suppresses T cell function.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Materials Science, Biomaterials
Nian Liu, Xiangyu Xiao, Ziqiang Zhang, Chun Mao, Mimi Wan, Jian Shen
Summary: Cancer vaccines are a promising therapeutic strategy in clinical oncology, stimulating antitumor immunity to fight against cancer. However, there are several challenges that hinder their broad clinical translation.
ACS BIOMATERIALS SCIENCE & ENGINEERING
(2023)
Article
Oncology
Mei Feng, Zhongwei Zhao, Mengxuan Yang, Jiansong Ji, Di Zhu
Summary: Colorectal cancer is the leading cause of cancer death worldwide, with therapeutic strategies including surgery, chemotherapy, radiotherapy, and other approaches. T-cell-based immunotherapy has shown promising responses in other cancers, but most CRC patients are resistant to immunotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors have shown encouraging results in some cancers, but are only effective for a subset of CRC patients with microsatellite instability. Other immunotherapies are currently being used against CRC.
Letter
Gastroenterology & Hepatology
H. Curtis, S. Jones, P. Treasure
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2014)
Article
Oncology
Richard Harrop, William H. Shingler, Mike McDonald, Peter Treasure, Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, Jackie de Belin, Michelle Kelleher, Madusha Goonewardena, Stuart Naylor
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2011)
Article
Oncology
Richard Harrop, Peter Treasure, Jackie de Belin, Michelle Kelleher, Gemma Bolton, Stuart Naylor, William H. Shingler
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2012)
Article
Pharmacology & Pharmacy
S. W. Duffy, F. P. Treasure
PHARMACEUTICAL STATISTICS
(2011)
Meeting Abstract
Oncology
N. G. Burnet, P. Nasr, G. Yip, J. E. Scaife, T. House, S. J. Thomas, F. Harris, P. J. Owen, P. Hull, F. P. Treasure
RADIOTHERAPY AND ONCOLOGY
(2014)
Article
Biotechnology & Applied Microbiology
Caroline V. Hacker, Conrad A. Vink, Theresa W. Wardell, Sheena Lee, Peter Treasure, Susan M. Kingsman, Kyriacos A. Mitrophanous, James E. Miskin
Article
Pharmacology & Pharmacy
P Treasure
PHARMACEUTICAL STATISTICS
(2003)
Article
Dermatology
TW Davies, FP Treasure, AA Welch, NE Day
BRITISH JOURNAL OF DERMATOLOGY
(2002)
Article
Public, Environmental & Occupational Health
J McCann, P Treasure, S Duffy
JOURNAL OF MEDICAL SCREENING
(2004)